Canagliflozin for advanced kidney disease with MRI study
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if canagliflozin, a diabetes medication, can help people with very advanced kidney disease or who recently started dialysis. It uses MRI scans to see how the drug affects the heart and kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney disease (eGFR < 20) or started dialysis in the last 6 months
- You have at least one of: heart muscle thickening, heart failure hospitalization, heart or blood vessel disease in the last year, type 2 diabetes, or high protein in urine
- You do not have type 1 diabetes
- You do not have a history of ketoacidosis (a serious diabetes complication)
- You can undergo an MRI without a pacemaker or certain metal implants
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
This trial tests canagliflozin to see if it lowers “vascular inflammation” in people with diabetes and stable coronary artery disease. It may help reduce harmful inflammation signals that can raise future heart risk.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This study tests whether the drug canagliflozin (a type of diabetes medicine) is safe and works in people on dialysis. It may help improve fluid balance or blood sugar control in hemodialysis patients.
This study tests a drug called henagliflozin (a type of SGLT2 inhibitor) to see if it can slow kidney decline in people with advanced chronic kidney disease who are not yet on dialysis. You may receive the drug or a placebo, and the trial will follow your kidney health over time.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
Hear when a new ESRD, CKD Stage 4, CKD Stage 5 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.